%0 Journal Article
%T COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2.
%A Shah SMI
%A Yasmin F
%A Memon RS
%A Jatoi NN
%A Savul IS
%A Kazmi S
%A Monawwer SA
%A Zafar MDB
%A Asghar MS
%A Tahir MJ
%A Lee KY
%J Brain Behav
%V 12
%N 12
%D 12 2022
%M 36306401
暂无%R 10.1002/brb3.2789
%X This review highlights the potential mechanisms of neuromuscular manifestation of COVID-19, especially myasthenia gravis (MG).<BR>An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020.<BR>Exacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID-19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders.<BR>Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.